# Twist Bioscience Corp: overview

TWST · Nasdaq · CIK 1581280 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Sep 30

Pages: [Overview](/companies/twst.md) · [Financials](/companies/twst/financials.md) · [Filings](/companies/twst/filings.md) · [Insiders](/companies/twst/insiders.md)

Latest reported revenue: [$118.4m](/filings/0001581280-26-000047.md) for Q3 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 3, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax, accession 0001581280-26-000047).

## Last eight quarters

| Line item | Unit | Q4 FY2024 (2024-09-30) | Q1 FY2025 (2024-12-31) | Q2 FY2025 (2025-03-31) | Q3 FY2025 (2025-06-30) | Q4 FY2025 (2025-09-30) | Q1 FY2026 (2025-12-31) | Q2 FY2026 (2026-03-31) | Q3 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [84.7 d](/filings/0001581280-25-000025.md) | [88.7](/filings/0001581280-26-000029.md) | [92.8](/filings/0001581280-26-000040.md) | [96.1](/filings/0001581280-26-000047.md) | [99.0 d](/filings/0001581280-25-000025.md) | [104](/filings/0001581280-26-000029.md) | [111](/filings/0001581280-26-000040.md) | [118](/filings/0001581280-26-000047.md) |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | [(42.5%) d](/filings/0001581280-25-000025.md) | [(39.1%)](/filings/0001581280-26-000029.md) | [(44.8%)](/filings/0001581280-26-000040.md) | [(31.4%)](/filings/0001581280-26-000047.md) | [(30.2%) d](/filings/0001581280-25-000025.md) | [(31.7%)](/filings/0001581280-26-000029.md) | [(41.4%)](/filings/0001581280-26-000040.md) | [(30.6%)](/filings/0001581280-26-000047.md) |
| Net margin | % | [(40.9%) d](/filings/0001581280-25-000025.md) | [(35.6%)](/filings/0001581280-26-000029.md) | [(42.4%)](/filings/0001581280-26-000040.md) | [21.2%](/filings/0001581280-26-000047.md) | [(27.4%) d](/filings/0001581280-25-000025.md) | [(29.4%)](/filings/0001581280-26-000029.md) | [(39.8%)](/filings/0001581280-26-000040.md) | [(29.6%)](/filings/0001581280-26-000047.md) |
| Diluted EPS | $ per share | not reported | [(0.53)](/filings/0001581280-26-000029.md) | [(0.66)](/filings/0001581280-26-000040.md) | [0.33](/filings/0001581280-26-000047.md) | not reported | [(0.50)](/filings/0001581280-26-000029.md) | [(0.71)](/filings/0001581280-26-000040.md) | [(0.56)](/filings/0001581280-26-000047.md) |
| Free cash flow | $m | [(17.3) d](/filings/0001581280-25-000025.md) | [(23.7)](/filings/0001581280-26-000029.md) | [(17.1) d](/filings/0001581280-26-000040.md) | [(10.6) d](/filings/0001581280-26-000047.md) | [(24.2) d](/filings/0001581280-25-000025.md) | [(34.8)](/filings/0001581280-26-000029.md) | [(25.4) d](/filings/0001581280-26-000040.md) | [(8.6) d](/filings/0001581280-26-000047.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 12-month figure less the 9-month figure; 6-month figure less the 3-month figure; 9-month figure less the 6-month figure.

## Last five fiscal years

| Line item | Unit | FY2021 (2021-09-30) | FY2022 (2022-09-30) | FY2023 (2023-09-30) | FY2024 (2024-09-30) | FY2025 (2025-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [132](/filings/0001628280-23-039767.md) | [204](/filings/0001628280-24-048262.md) | [245](/filings/0001581280-25-000025.md) | [313](/filings/0001581280-25-000025.md) | [377](/filings/0001581280-25-000025.md) |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | [(115.4%)](/filings/0001628280-23-039767.md) | [(115.3%)](/filings/0001628280-24-048262.md) | [(88.6%)](/filings/0001581280-25-000025.md) | [(70.6%)](/filings/0001581280-25-000025.md) | [(36.2%)](/filings/0001581280-25-000025.md) |
| Net margin | % | [(114.9%)](/filings/0001628280-23-039767.md) | [(107.0%)](/filings/0001628280-24-048262.md) | [(83.5%)](/filings/0001581280-25-000025.md) | [(66.7%)](/filings/0001581280-25-000025.md) | [(20.6%)](/filings/0001581280-25-000025.md) |
| Diluted EPS | $ per share | [(3.15)](/filings/0001628280-23-039767.md) | [(4.04)](/filings/0001628280-24-048262.md) | [(3.60)](/filings/0001581280-25-000025.md) | [(3.60)](/filings/0001581280-25-000025.md) | [(1.30)](/filings/0001581280-25-000025.md) |
| Free cash flow | $m | [(139)](/filings/0001628280-23-039767.md) | [(226)](/filings/0001628280-24-048262.md) | [(170)](/filings/0001581280-25-000025.md) | [(69.2)](/filings/0001581280-25-000025.md) | [(75.6)](/filings/0001581280-25-000025.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax.
- Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.

Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing.

## Insider purchases and sales

The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/twst/insiders.md)

| Date | Insider | Role | Transaction | Shares | Reported price | Value | Filing |
| --- | --- | --- | --- | ---: | ---: | ---: | --- |
| 2026-10-23 | [Finn Patrick John](/insiders/1755970.md) | President and COO, Officer | Sale (S) | 2,245 | $134.589 | $302.2k | [Form 4](/filings/0001214659-26-013283.md) |

## Funds that report holding it

From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md)

| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | --- | --- |
| [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $600.2m | 5,833,891 |  | Added +279,529 |
| [Artisan Partners Limited Partnership](/funds/1466153.md) | 2026-06-30 | $494.0m | 4,802,017 |  | Reduced −1,565,760 |
| [FMR LLC](/funds/315066.md) | 2026-06-30 | $483.8m | 4,703,044 |  | Added +2,813,099 |
| [ARK Investment Management LLC](/funds/1697748.md) | 2026-06-30 | $468.1m | 4,549,803 |  | Reduced −1,792,930 |
| [STATE STREET CORP](/funds/93751.md) | 2026-06-30 | $332.6m | 3,232,532 |  | Reduced −438,150 |
| [VANGUARD PORTFOLIO MANAGEMENT LLC](/funds/2100121.md) | 2026-06-30 | $290.6m | 2,824,989 |  | Added +175,888 |
| [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $277.7m | 2,699,280 |  | Added +60,236 |
| [EdgePoint Investment Group Inc.](/funds/1481669.md) | 2026-06-30 | $259.4m | 2,521,635 |  | Reduced −2,860,886 |
| [WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC](/funds/1644956.md) | 2026-06-30 | $223.7m | 2,174,594 |  | Reduced −3,095,124 |
| [FARALLON CAPITAL MANAGEMENT, L.L.C.](/funds/909661.md) | 2026-06-30 | $219.8m | 2,136,400 |  | Added +708,750 |

## Recent filings

[All 1,611 filings](/companies/twst/filings.md)

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-08-19 | 17:24 ET | [8-K](/filings/0001104659-26-098830.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001104659-26-098830 |
| 2026-08-19 | 18:15 ET | [8-K](/filings/0001581280-26-000050.md) | 7.01 Regulation FD disclosure | 0001581280-26-000050 |
| 2026-08-05 | 17:27 ET | [8-K](/filings/0001104659-26-091280.md) | 1.01 Entry into a material agreement; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001104659-26-091280 |
| 2026-08-03 | 16:10 ET | [10-Q](/filings/0001581280-26-000047.md) | Quarterly report, period 2026-06-30 | 0001581280-26-000047 |
| 2026-08-03 | 07:21 ET | [8-K](/filings/0001581280-26-000044.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001581280-26-000044 |
| 2026-05-04 | 16:28 ET | [10-Q](/filings/0001581280-26-000040.md) | Quarterly report, period 2026-03-31 | 0001581280-26-000040 |
| 2026-05-04 | 07:21 ET | [8-K](/filings/0001581280-26-000037.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001581280-26-000037 |
| 2026-02-26 | 16:19 ET | [10-Q/A](/filings/0001581280-26-000029.md) | Quarterly report, amended, period 2025-12-31 | 0001581280-26-000029 |
| 2026-02-17 | 07:09 ET | [8-K](/filings/0001104659-26-015730.md) | 3.02 Unregistered sale of equity; 8.01 Other events; 9.01 Financial statements and exhibits | 0001104659-26-015730 |
| 2026-02-06 | 17:25 ET | [8-K](/filings/0001581280-26-000022.md) | 5.07 Shareholder vote results | 0001581280-26-000022 |

## Latest annual report

[Form 10-K for the fiscal year ended Sep 30, 2025](/filings/0001581280-25-000025.md), filed Nov 17, 2025.

## Forecast league

Q4 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/1b0d22c5-8339-4997-b6a6-0b8b6eab86dd)

## About the filer

- CIK: 1581280
- Tickers: TWST
- Exchange: Nasdaq
- SIC code: 2836 Biological Products, (No Diagnostic Substances)
- State of incorporation: DE
- Filer category: Large accelerated filer

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 27, 2026, 16:07 ET. No prices; not investment advice.